Browse Category

NYSE:MRK News 20 December 2025 - 30 December 2025

Merck stock slips as 2025 winds down; MRK traders turn to Feb. 3 earnings next

Merck stock slips as 2025 winds down; MRK traders turn to Feb. 3 earnings next

NEW YORK, December 29, 2025, 20:35 ET — Market closed. Merck & Co (MRK) shares eased on Monday, last trading down about 0.1% at $106.62 after ranging between $106.44 and $107.56. Trading volume was about 8.1 million shares. The small move mattered mainly for timing. With the final three sessions of 2025 ahead, investors have been rebalancing portfolios in light holiday volume, a stretch that can exaggerate moves even in large, liquid names. Merck is also a bellwether for big-cap pharmaceuticals, a group investors often treat as “defensive” — stocks that can hold up better when growth shares wobble —
Merck (MRK) stock holds steady as Wall Street cools into year-end trade

Merck (MRK) stock holds steady as Wall Street cools into year-end trade

NEW YORK, December 29, 2025, 3:12 PM ET — Regular session Merck & Co shares were little changed on Monday afternoon, up 0.01% at $106.79. The muted move mattered because investors have been shifting toward steadier corners of the market as 2025 winds down, a period that can amplify small price swings on lighter volumes. Health-care stocks largely held their ground, with the Health Care Select Sector SPDR ETF down 0.05%, as traders stayed selective in year-end positioning. Wall Street’s main indexes slipped as heavyweight technology names retreated from last week’s gains. “This is (not) the beginning of the end
29 December 2025
Merck stock holds steady as year-end trading thins and Wall Street slips

Merck stock holds steady as year-end trading thins and Wall Street slips

NEW YORK, December 29, 2025, 12:47 ET — Regular session Merck & Co (MRK.N) shares were down 0.1% at $106.68 in midday trading on Monday, showing relative resilience as U.S. stocks drifted lower in thin year-end trade. The S&P 500-linked SPDR ETF (SPY) fell 0.6% and the Nasdaq-100 tracker (QQQ) slid 0.7%. The muted move matters because the market is entering a holiday-shortened stretch where lighter volumes can amplify day-to-day swings, even without fresh company news. Traders are also positioning for a cluster of late-December data and central bank signals that could shape early-2026 risk appetite. Reuters+1 On Monday, a
Merck stock holds near 52-week high as year-end trading turns to Fed minutes

Merck stock holds near 52-week high as year-end trading turns to Fed minutes

NEW YORK, December 28, 2025, 21:37 ET — Market closed Merck & Co shares finished the last U.S. session up 0.3% at $106.78, closing just below a 52-week high after a quiet, post-Christmas session left the broader market marginally lower. Yahoo Finance+1 The move matters for investors because late-December flows can push big, liquid drugmakers around even without fresh company news, as portfolios rebalance into year-end and trading volumes stay light. Reuters+1 Attention is also shifting to interest-rate expectations, which can influence valuations for defensive, dividend-paying stocks such as large pharmaceuticals. Minutes from the Federal Reserve’s most recent meeting are
Merck (MRK) Stock Today: Latest News, Analyst Forecasts, and What Investors Should Watch Before Monday’s Open

Merck (MRK) Stock Today: Latest News, Analyst Forecasts, and What Investors Should Watch Before Monday’s Open

NEW YORK, Dec. 28, 2025, 11:52 a.m. ET — Market Closed Merck & Co., Inc. (NYSE: MRK) heads into the final trading days of 2025 with shares hovering near fresh highs after a late-December climb that has put the pharmaceutical giant back in the spotlight for both defensive investors and catalyst-driven traders. With U.S. stock markets closed for the weekend, attention shifts to what could shape MRK when the regular session resumes Monday—ranging from year-end positioning and Fed expectations to analyst outlooks focused on Merck’s ability to grow beyond Keytruda. Reuters Where Merck stock stands with markets closed Merck stock
Merck (MRK) Stock Update: Weekend Wrap, Latest Headlines, Analyst Targets, and What to Watch Before Monday’s Open

Merck (MRK) Stock Update: Weekend Wrap, Latest Headlines, Analyst Targets, and What to Watch Before Monday’s Open

NEW YORK, Dec. 27, 2025, 11:25 a.m. ET — Market closed (weekend) Merck & Co., Inc. (NYSE: MRK) heads into the final days of 2025 with investors weighing a steady holiday-week climb in the shares against a familiar set of longer-term questions: how fast Merck can broaden growth beyond Keytruda, how policy and pricing shifts may reshape demand, and what the next wave of pipeline milestones could mean for earnings power into 2026 and beyond. With U.S. stock exchanges closed for the weekend, the next actionable moment for MRK traders will be Monday’s session, when liquidity returns and any weekend
27 December 2025
Merck Stock (MRK) News and Forecasts: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Cidara Acquisition in Focus Ahead of the Next Market Session

Merck Stock (MRK) News and Forecasts: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Cidara Acquisition in Focus Ahead of the Next Market Session

As of 2:34 a.m. ET in New York on Saturday, December 27, 2025, U.S. stock markets are closed for the weekend.Merck & Co., Inc. (NYSE: MRK) was last quoted around $106.78, up about 0.33% versus its prior close, based on the latest available pricing feed. With year-end trading under way and liquidity often thinner around the holidays, Merck is heading into the next session with an unusually packed headline stack: policy-driven drug pricing news, FDA review acceleration for two experimental therapies, and portfolio diversification via M&A—all against the backdrop of investors constantly re-litigating the same big question: how Merck replaces
Merck (MRK) Stock Update: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Analyst Targets as Wall Street Heads Into New Year Week

Merck (MRK) Stock Update: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Analyst Targets as Wall Street Heads Into New Year Week

As of 10:40 p.m. ET in New York on Friday, Dec. 26, 2025, U.S. markets have wrapped up the post-Christmas session and are heading into a weekend — leaving investors to digest a fresh cluster of headline catalysts around Merck & Co., Inc. (NYSE: MRK) before the next opening bell. Merck shares finished the regular session around $106.78, after trading in a $106.03 to $107.05 range on the day — with thin holiday-week liquidity still shaping tape action across the market. StockAnalysis What happened in the broader market — and why it matters for MRK Friday’s trading was muted, with
Merck (MRK) Stock: Key News, Analyst Targets, and Catalysts to Know Before the Market Opens Dec. 26, 2025

Merck (MRK) Stock: Key News, Analyst Targets, and Catalysts to Know Before the Market Opens Dec. 26, 2025

U.S. stock markets were closed for Christmas Day (Thursday, Dec. 25, 2025) and are scheduled to reopen Friday, Dec. 26 after a holiday-early close on Wednesday, Dec. 24. New York Stock Exchange That timing matters for Merck & Co., Inc. (NYSE: MRK) investors because the stock has been moving on a cluster of late-December headlines—ranging from drug-pricing policy to pipeline fast-tracks and approvals, plus a wave of fresh analyst target changes. Below is what to know heading into the Dec. 26 open, based on the latest available reporting and company disclosures. MRK stock snapshot heading into Dec. 26 What’s driving
Merck & Co. (MRK) Enters 2026 in the Spotlight: BMO Upgrade to $130, FDA Fast-Track Vouchers and TrumpRx Pricing Deal Reframe the Post-Keytruda Story

Merck & Co. (MRK) Enters 2026 in the Spotlight: BMO Upgrade to $130, FDA Fast-Track Vouchers and TrumpRx Pricing Deal Reframe the Post-Keytruda Story

December 25, 2025 — Even with U.S. markets closed for Christmas Day, Merck & Co., Inc. (NYSE: MRK) is ending 2025 as one of the most-watched large-cap pharma names on Wall Street. The stock closed at $106.45 on Wednesday, Dec. 24, and commentary published today points to a six-day winning streak that has pushed investors back into “what’s next” mode: how Merck replaces Keytruda’s eventual loss of exclusivity while navigating a shifting U.S. drug-pricing backdrop. Nasdaq Below is a comprehensive, as-of-today roundup of the most consequential news, forecasts, and analyst analysis shaping Merck’s outlook heading into 2026—covering oncology, cardiovascular ambitions,
25 December 2025
Merck (MRK) Stock News on Dec. 25, 2025: BMO Lifts Target to $130 as FDA Fast-Track Vouchers and Keytruda Data Fuel Momentum

Merck (MRK) Stock News on Dec. 25, 2025: BMO Lifts Target to $130 as FDA Fast-Track Vouchers and Keytruda Data Fuel Momentum

December 25, 2025 — Merck & Co., Inc. (NYSE: MRK) is ending 2025 with something investors tend to enjoy: momentum with a story behind it. Even with U.S. markets closed for Christmas Day, Merck shares are in focus after a late-December climb that pushed the stock to fresh highs, helped along by a major Wall Street upgrade and a burst of pipeline and regulatory headlines. MarketBeat Below is what’s moving Merck stock, what the latest MRK forecasts imply for 2026, and the near-term catalysts (and risks) that could decide whether this rally is the start of a new chapter—or just
Merck (MRK) Stock After Hours Today: Shares Hit a New 52-Week High on Dec. 24, 2025 — What to Know Before U.S. Markets Reopen

Merck (MRK) Stock After Hours Today: Shares Hit a New 52-Week High on Dec. 24, 2025 — What to Know Before U.S. Markets Reopen

NEW YORK — December 24, 2025: Merck & Co., Inc. (NYSE: MRK) ended a holiday-shortened Christmas Eve session near $106.45, up about 1.3% on the day, and held close to those levels in thin after-hours trading. MarketBeat The move capped a strong late-December run for the pharmaceutical blue chip and came as the broader U.S. market pushed to fresh records in a “Santa rally” setup—an upbeat backdrop that helped lift several Dow components, including Merck. Reuters+1 Below is what investors and traders should know after the bell on 12/24/2025, and what to watch before the next U.S. cash-session open (note:
Merck Stock Forecast and News Roundup for December 24, 2025: MRK Hits a New 52-Week High as Wall Street Reprices 2026 Catalysts

Merck Stock Forecast and News Roundup for December 24, 2025: MRK Hits a New 52-Week High as Wall Street Reprices 2026 Catalysts

Merck & Company, Inc. stock is ending 2025 on a strong note. On December 24, 2025, shares of Merck (MRK) pushed to a fresh 12‑month high around the $106 level, extending a powerful late‑year rally that has put the pharma bellwether back in the spotlight. MarketBeat+2Investing.com+2 This move isn’t happening in a vacuum. Today’s MRK price action sits at the intersection of three market themes that have dominated Merck headlines into Christmas Eve: Below is a comprehensive, publication-ready roundup of the current news, forecasts, and analysis investors are reading as of December 24, 2025, and what it could mean for
Merck (MRK) Stock After Hours Today (Dec. 23, 2025): Shares Slip Slightly After the Close as Investors Track TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Fresh Wall Street Targets

Merck (MRK) Stock After Hours Today (Dec. 23, 2025): Shares Slip Slightly After the Close as Investors Track TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Fresh Wall Street Targets

NEW YORK — Merck & Co., Inc. (NYSE: MRK) ended regular trading Tuesday, December 23, 2025, at $105.04, and eased modestly in after-hours trading to about $104.81 (down roughly 0.2%) as of early evening in New York. Google The move after the bell was small, but MRK’s two-day run has been anything but: the stock is coming off a sharp gain on Monday (Dec. 22) and is trading within reach of its 52-week high—a setup that often makes the next session more about “what’s next” than what just happened. StockAnalysis+1 Below is what investors and traders will want on their
Merck (MRK) Stock News and Forecasts for Dec. 23, 2025: TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Wall Street’s Latest Targets

Merck (MRK) Stock News and Forecasts for Dec. 23, 2025: TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Wall Street’s Latest Targets

Merck & Co., Inc. (NYSE: MRK) is closing in on year-end with a rare mix of policy-driven headlines, regulatory acceleration, and pipeline catalysts that are shaping investor expectations for 2026 and beyond. From a White House-backed drug-pricing framework that offers tariff relief to drugmakers, to the FDA’s fast-track voucher program attaching itself to two Merck assets with blockbuster potential, MRK stock is being evaluated not just on quarterly numbers—but on whether Merck can extend growth beyond Keytruda while navigating intensifying U.S. drug-pricing scrutiny. Reuters+2Reuters+2 Below is a comprehensive, publication-ready roundup of today’s MRK stock action, the key news moving the
Merck (MRK) Stock After Hours Today (Dec. 22, 2025): Why Shares Jumped and What to Watch Before Tuesday’s Open

Merck (MRK) Stock After Hours Today (Dec. 22, 2025): Why Shares Jumped and What to Watch Before Tuesday’s Open

Merck & Co. (NYSE: MRK) is ending Monday’s session with fresh momentum—and investors heading into Tuesday’s open (Dec. 23, 2025) have a lot to digest. After a strong regular-session rally, Merck stock closed at $104.72, up $3.63 (+3.59%), and traded slightly lower in after-hours at about $104.69 as of early evening. The day’s range ran from $100.40 to $104.95, putting MRK within roughly 1% of its 52-week high ($105.84)—a level traders will be watching closely into the holiday-shortened week. Investing.com+2Finviz+2 Merck stock price recap: the key numbers after the bell Here are the most important MRK data points investors are
23 December 2025
Merck (MRK) Stock: What to Know Before the Market Opens on Dec. 22, 2025

Merck (MRK) Stock: What to Know Before the Market Opens on Dec. 22, 2025

Dateline: Dec. 22, 2025 (pre-market) — Merck & Co., Inc. (NYSE: MRK) enters the new week with a fast-moving mix of policy headlines, FDA acceleration news, and shifting analyst sentiment—all landing on top of the company’s longer-running story: strong near-term cash flow powered by Keytruda, paired with a multi-year push to diversify before Keytruda’s late-decade patent cliff. Below is what investors and everyday readers should know before U.S. markets open. Merck stock price snapshot and near-term calendar The big headline: Merck’s new U.S. drug-pricing agreement and the TrumpRx push The most immediate headline risk—and potential catalyst—into Monday is Merck’s newly
22 December 2025
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Christmas week is usually about thin liquidity and shorter trading hours, not blockbuster headlines. But pharma and biotech stocks head into the final full week of the year with a rare mix of policy shockwaves, deal-making, and FDA-driven volatility—all clustered around Dec. 19–21, 2025. From the White House’s sweeping “most-favored-nation” (MFN) push on U.S. drug prices to BioMarin’s largest-ever acquisition and fresh FDA approvals, the setup into year-end has become more headline-sensitive than the calendar would suggest. Here’s what investors and traders should be watching in pharma stocks in the week ahead. Christmas week trading: shorter sessions, fewer buyers, faster
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

As of December 20, 2025, healthcare stocks are heading into year-end with a rare mix of policy clarity and policy risk—often at the same time. In the past 48 hours, the sector has been hit by major U.S. drug-pricing announcements, renewed focus on insurance premiums, and a fresh run of deal and IPO headlines that are reshaping investor expectations for 2026. Reuters+3Reuters+3Reuters+3 Below is a comprehensive roundup of the most market-moving healthcare news, plus the latest forecasts and sector analysis shaping how investors are positioning across pharma, biotech, managed care, medtech, and healthcare services into 2026. 1) Drug pricing is
Merck (MRK) Stock After Hours on Dec. 19, 2025: Trump Drug-Pricing Deal, FDA Fast-Track Vouchers, and What to Watch Before Markets Reopen

Merck (MRK) Stock After Hours on Dec. 19, 2025: Trump Drug-Pricing Deal, FDA Fast-Track Vouchers, and What to Watch Before Markets Reopen

Merck & Co., Inc. (NYSE: MRK) finished Friday’s regular session (Dec. 19, 2025) modestly higher, then eased slightly in after-hours trading as investors digested a headline-heavy day featuring U.S. drug-pricing policy moves and FDA acceleration for two major Merck pipeline assets. Below is what happened after the bell, why it matters, and the key items to track before the next U.S. market open (Monday, Dec. 22, 2025). MRK stock price after the bell: the key numbers Merck shares closed at $101.09, up $0.40 (+0.40%) on Friday. Zacks+1 In after-hours trading, MRK was slightly lower, trading around $100.9–$101.0 in early evening

Stock Market Today

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

7 February 2026
Home Depot shares rose 0.7% to $385.15 Friday, trading between $379.10 and $386.37. Investors await a delayed U.S. jobs report Wednesday and CPI data Friday, both postponed by a brief government shutdown. Home Depot reports fourth-quarter earnings Feb. 24. The Dow closed above 50,000 for the first time.
JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

7 February 2026
JPMorgan shares rose 3.95% to $322.40 Friday, outpacing other major banks as U.S. stocks rallied and the Dow closed above 50,000 for the first time. The bank recently completed a $3 billion subordinated notes offering. Investors are watching for delayed U.S. jobs data and inflation figures next week, ahead of JPMorgan’s Feb. 23 company update.
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
SK hynix stock price slips into Monday after S&P upgrade, tech selloff

SK hynix stock price slips into Monday after S&P upgrade, tech selloff

7 February 2026
SK hynix shares closed at 839,000 won, down 0.36% Friday and 8% for the week, as tech stocks retreated across Asia. S&P Global Ratings upgraded the chipmaker to “BBB+” with a positive outlook, citing strong HBM sales. The KOSPI fell 1.4% Friday, ending a six-week winning streak. Traders await Monday’s Seoul open for signs of further tech weakness.
Go toTop